Terminal / Weight Loss

Cagrilintide

Phase 3

aka AM833

Long-acting amylin analog, usually run alongside semaglutide as CagriSema.

Mechanism

An amylin receptor agonist that drives satiety and slows gastric emptying, a different lever than GLP-1. Stack it with semaglutide (that combo is CagriSema) and the two mechanisms add up.

Regulatory & Safety Status

Investigational (Novo Nordisk), late-stage trials. Not approved yet.

Research

2026Annals of internal medicine

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians

2026Nature metabolism

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance

2026Nature metabolism

Cellular loci for cagrilintide action identified

2026The lancet. Diabetes & endocrinology

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

2024PubMed

Latest cagrilintide research

Related Compounds

Weight Loss

Semaglutide

Approved

Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.

Weight Loss

Retatrutide

Phase 3

Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.